Rituximab Targets B Cells in Cancer and Autoimmune Disease

If your doctor has mentioned rituximab, you probably have questions. What does it do? Is it safe?

Rituximab is a prescription monoclonal antibody. It helps treat certain blood cancers and autoimmune diseases by targeting CD20-positive B cells. For many patients, it can be an effective part of care — but it does require planned monitoring, because infusion reactions, infections, and other Chemotherapy Side Effects: What to Expect and How to Manage" class="ahp-ilk">side effects can occur.

What rituximab is and why it is used

Rituximab is a laboratory-made medicine called a monoclonal antibody. It is designed to attach to a protein called CD20 found on the surface of certain B cells, a type of white blood cell. By targeting these cells, rituximab can help treat some diseases in which B cells are cancerous, overactive, or contributing to inflammation.

Doctors use rituximab in several different settings. It is commonly prescribed for some B-cell blood cancers, such as non-Hodgkin lymphoma and <a href="https://acibademhealthpoint.com/diseases/chronic-lymphocytic-leukemia/”>chronic lymphocytic leukemia, and for certain autoimmune or inflammatory diseases, including rheumatoid arthritis and some forms of vasculitis. In some situations, it may also be used for other immune-mediated conditions when specialists judge that the benefits outweigh the risks.

Because rituximab affects the immune system, your treatment will be tailored to you. The schedule, the number of infusions, and whether it’s combined with other medicines all depend on your diagnosis, treatment goals, previous therapies, and overall health. That’s why you’ll often see an oncology, hematology, rheumatology, or immunology specialist when rituximab is on the table.

How rituximab works in the body

Rituximab works by binding to CD20-positive B cells. Once attached, it helps the immune system recognize and remove these cells. In cancers arising from B cells, this can reduce the number of abnormal cells. In autoimmune disease, lowering B-cell activity can decrease the production of harmful antibodies and calm inflammation.

The effect is not immediate in every condition. Some patients notice gradual improvement over weeks to months, especially in autoimmune diseases. Others receive rituximab as part of a broader treatment plan that may also include steroids, chemotherapy, or other immune-targeting medicines.

Because B cells are part of normal immune defense, lowering them can also increase vulnerability to infections. This balance between benefit and risk is a central part of decision-making before treatment begins. For cancer care, rituximab is often discussed alongside chemotherapy or other targeted therapies when a broader treatment strategy is needed.

Conditions rituximab may treat

Rituximab has approved and established uses that vary by country, health authority, and clinical guideline. In cancer care, it is widely used for some B-cell lymphomas and leukemias. For patients with lymphoma, it may be given alone or combined with other medicines, depending on the subtype and stage. It is also used in selected patients with leukemia, especially when the disease involves CD20-positive B cells.

Outside oncology, rituximab is used for autoimmune diseases in which B cells play an important role. These include rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and certain blistering skin diseases or kidney-related immune disorders in carefully selected cases. In these settings, treatment decisions are often made by specialist teams after reviewing symptoms, prior treatment response, and safety factors.

Not everyone with one of these diagnoses will need rituximab. Other medicines may suit you better depending on how severe the disease is, your age, pregnancy considerations, infection history, or other conditions you have. It’s worth asking your team directly: why rituximab, what are the alternatives, and what results do you expect?

How rituximab is given and what to expect during treatment

Rituximab is most often given by intravenous infusion in a hospital or infusion center. Some patients may receive it over several hours, especially with early doses, because the care team watches closely for infusion reactions. In certain settings, a subcutaneous form may be used after the medical team decides it is appropriate.

Before the infusion, clinicians often give premedication, such as acetaminophen, antihistamines, or sometimes corticosteroids, to reduce the chance of reactions. During treatment, nurses monitor temperature, pulse, blood pressure, breathing, and symptoms such as chills, itching, rash, or shortness of breath. If a reaction happens, the infusion may be slowed or paused and supportive treatment provided.

The treatment schedule depends on the disease being treated. Some patients receive a short series of doses; others have maintenance therapy or repeat courses months later. In cancer care, rituximab may be part of a larger program that includes immunotherapy or other drug combinations. The care team explains how often treatment is planned and what tests are needed between visits.

Many patients can go home the same day after infusion. Fatigue can occur, so arranging transportation or lighter activities afterward may be helpful, especially after the first dose. The team usually provides written instructions about possible side effects and when to call for advice.

Side effects, risks, and safety monitoring

Like all strong immune-targeting medicines, rituximab can cause side effects. Infusion reactions are among the best known and may include fever, chills, flushing, rash, headache, nausea, throat irritation, or breathing difficulty. These reactions are often most likely with the first infusion and are usually managed by slowing treatment and giving supportive medications.

Infections matter too, because rituximab dampens part of your immune defense. You may be at higher risk of bacterial, viral, or fungal infections — especially if you’re also on steroids, chemotherapy, or other immunosuppressive drugs. Your doctor will often check blood counts and may order more tests if an infection is suspected.

One thing your doctor won’t skip: hepatitis B screening. Rituximab can allow a past hepatitis B infection to wake up again. Depending on the results, some patients need preventive antiviral treatment and close follow-up. Your vaccination plan may also be reviewed beforehand, since some vaccines work better before B-cell depletion begins.

Other possible risks include low blood counts, heart-related symptoms during infusion, bowel complications in selected patients, and rare but serious neurological problems such as progressive multifocal leukoencephalopathy. Although these serious events are uncommon, patients should promptly report new confusion, weakness, vision changes, severe headache, persistent fever, or unusual bruising. In some complex cases, doctors may also coordinate care with bone marrow transplantation teams when rituximab is part of broader blood disorder treatment planning.

Tests before treatment and follow-up after infusions

Safe rituximab treatment starts with a careful review before the first dose. Doctors usually ask about prior infections, hepatitis exposure, vaccination history, heart or lung problems, pregnancy plans, and all current medications. Blood tests commonly include a complete blood count and chemistry panel, and many patients also have hepatitis B testing before treatment begins.

Depending on the condition, additional tests may be needed. These can include imaging studies, immune marker tests, kidney function checks, or assessments of disease activity. For cancer care, staging and pathology results help determine whether rituximab is likely to be beneficial. For autoimmune diseases, specialists may track symptoms, inflammatory markers, and organ function over time.

After treatment starts, follow-up is used to measure both effectiveness and safety. Some patients improve gradually, while others need changes to the treatment plan if symptoms continue or side effects become difficult. If rituximab is being used within a multidisciplinary cancer program, specialists may also discuss supportive options and advanced planning such as stem cell transplant when clinically appropriate.

Self-care during rituximab treatment

There’s a lot you can do yourself during rituximab treatment. Stick to the plan your team gives you and keep every scheduled appointment. Wash your hands well, keep your distance from people who are clearly ill, and report early signs of infection. And ask before taking any vaccine, supplement, or new prescription medicine.

General healthy habits matter as well. Rest, balanced meals, regular fluids, and gentle activity as tolerated may help with energy and recovery. People with autoimmune diseases may also benefit from keeping a symptom diary so they can describe flares, pain, fatigue, or changes in function clearly at follow-up visits.

Don’t stop or delay treatment on your own unless a doctor advises it. If side effects come up, your care team can often adjust supportive medicines, timing, or monitoring rather than stopping treatment altogether. The more you tell them, the more safely they can tailor your care.

• Keep a current medication list and bring it to appointments.
• Ask what symptoms should trigger an urgent call.
• Discuss travel plans, dental work, and vaccines in advance.
• Tell the care team about fever, cough, rash, or unusual fatigue.

When to seek medical care

Patients should contact a doctor promptly if they develop fever, chills, a new cough, shortness of breath, painful urination, severe diarrhea, or any symptom that suggests infection. New rash, swelling, faintness, chest discomfort, or breathing trouble during or after an infusion also needs timely medical attention. It is always safer to ask early when symptoms are new or worsening.

Get checked urgently for unusual bruising or bleeding, severe weakness, confusion, trouble speaking, vision changes, or one-sided numbness. These symptoms don’t always mean something serious — but don’t ignore them. If you live with a chronic illness or a weakened immune system, you can become unwell quickly, so keep the bar for calling your care team low.

Near the end of treatment planning, some patients value coordinated review in centers with multiple specialties involved in blood disorders, cancer, and immune-mediated disease. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat conditions in which rituximab may be used, particularly for international patients who need organized evaluation and follow-up.

Frequently asked questions